(Anaveon) ANV700 is a novel proximity-activated IL-21 receptor agonist designed to selectively reinvigorate tumor-reactive PD-1 expressing T cells
Efficacy assessment with hPD-1
Abstract
Background
Selective delivery of IL-21 to PD-1+ cells through a Proximity-Activated Cytokine (PAC)IL-21 has the potential to increase the cytotoxicity and maintain survival of tumor reactive CD8+ T cells in chronic antigen exposure settings, such as cancer. Clinical studies with recombinant IL-21 showed promising therapeutic benefit, which was limited by dose-limiting toxicity and immunosuppressive effects on antigen-presenting cells. ANV700 addresses these limitations by targeting a novel proximity-activated IL-21 specifically to PD-1-expressing cells. This approach aims to reinvigorate tumor-specific T cells while minimizing off-target effects.
Scientific excellence
From model design to experimental results
Featured in 600+ scientific articles
Collaborative approach
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Robust validation data on catalog models
Generated with biopharma partners and in-house
Innovative technologies
and guaranteed freedom to operate
Easy access to models
Models with certified health status from professional breeders in US and Europe